A Case of Probable Multifocal Motor Neuropathy With Clinical Stability for Ten Years After a Single Treatment of Rituximab.
| Autor: | Gonzalez NL; Department of Neurology, Duke University Hospital, Durham, NC; and., Juel VC; Department of Neurology, Duke University Hospital, Durham, NC; and., Živković SA; Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical neuromuscular disease [J Clin Neuromuscul Dis] 2022 Mar 01; Vol. 23 (3), pp. 136-142. |
| DOI: | 10.1097/CND.0000000000000358 |
| Abstrakt: | Abstract: Multifocal motor neuropathy is a rare, immune-mediated motor neuropathy with asymmetric, often debilitating progressive weakness. The efficacy of intravenous immunoglobulin in this disease is well established; however, the response typically wanes over time. No other agent has shown similar therapeutic efficacy. We describe a case of anti-ganglioside GM1 IgM-positive multifocal motor neuropathy with typical incomplete and diminishing response to intravenous immunoglobulin over time. Sixteen years after symptom onset, rituximab was administered at 2 g/m2 over 2 weeks. No significant progression of disease has occurred over the following 10 years despite no additional treatments, including intravenous immunoglobulin, being given. Only case reports and small, mostly uncontrolled studies have reported the use of rituximab in multifocal motor neuropathy with mixed results. However, given its potential benefits and lack of an established second-line agent, treatment with rituximab may be considered in select patients with refractory multifocal motor neuropathy. Competing Interests: The authors report no conflicts of interest. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|